Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Franchini

Showing results (61-70 of 748) with videos related to

Pageof 75
Sort By:
Expert Opinion on Investigational Drugs|August 5, 2024
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatmentMassimo Franchini, Daniele Focosi
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 5, 2006
Recent acquisitions in acquired and congenital von Willebrand disordersMassimo Franchini, Giuseppe Lippi
American Journal of Hematology|July 27, 2005
Successful treatment of intestinal hemorrhage in a Jehovah's Witness patientDino Veneri, Massimo Franchini
Recenti Progressi in Medicina|June 28, 2005
[Autoimmune thrombocytopenia: diagnosis and treatment]Dino Veneri, Massimo Franchini
Blood Transfusion = Trasfusione Del Sangue|January 30, 2013
Target of prophylaxis in severe haemophilia: more than factor levelsAntonio Coppola, Massimo Franchini
Recenti Progressi in Medicina|October 19, 2005
[Heparin-induced thrombocytopenia]Massimo Franchini, Dino Veneri
Seminars in Thrombosis and Hemostasis|December 5, 2024
Advances in the Management of Hemophilia and Bleeding Disorders: Achievements and PerspectivesAntonio Coppola, Massimo Franchini
The Lancet. Haematology|December 22, 2015
Thalidomide for hereditary haemorrhagic telangiectasiaMassimo Franchini, Giuseppe Lippi
Circulation|September 21, 2016
Letter by Lippi and Franchini Regarding Article, "ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors"Giuseppe Lippi, Massimo Franchini
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 18, 2015
Evolutionary aspects of ABO blood group in humansMassimo Franchini, Carlo Bonfanti
Pageof 75

Showing results (61-70 of 748) with videos related to

Sort By:
Pageof 75
Expert Opinion on Investigational Drugs|August 5, 2024
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatmentMassimo Franchini, Daniele Focosi
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 5, 2006
Recent acquisitions in acquired and congenital von Willebrand disordersMassimo Franchini, Giuseppe Lippi
American Journal of Hematology|July 27, 2005
Successful treatment of intestinal hemorrhage in a Jehovah's Witness patientDino Veneri, Massimo Franchini
Recenti Progressi in Medicina|June 28, 2005
[Autoimmune thrombocytopenia: diagnosis and treatment]Dino Veneri, Massimo Franchini
Blood Transfusion = Trasfusione Del Sangue|January 30, 2013
Target of prophylaxis in severe haemophilia: more than factor levelsAntonio Coppola, Massimo Franchini
Recenti Progressi in Medicina|October 19, 2005
[Heparin-induced thrombocytopenia]Massimo Franchini, Dino Veneri
Seminars in Thrombosis and Hemostasis|December 5, 2024
Advances in the Management of Hemophilia and Bleeding Disorders: Achievements and PerspectivesAntonio Coppola, Massimo Franchini
The Lancet. Haematology|December 22, 2015
Thalidomide for hereditary haemorrhagic telangiectasiaMassimo Franchini, Giuseppe Lippi
Circulation|September 21, 2016
Letter by Lippi and Franchini Regarding Article, "ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors"Giuseppe Lippi, Massimo Franchini
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 18, 2015
Evolutionary aspects of ABO blood group in humansMassimo Franchini, Carlo Bonfanti
Pageof 75